Latest news
Vivani Medical Announces Successful Dosing of All - GlobeNewswireGlobeNewswire · Thu, 06 Aug 2026 12:00:00 GMTRactigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 11:56:14 GMTOak Hill Bio Announces Dosing of First Participant in - GlobeNewswireGlobeNewswire · Tue, 28 Jul 2026 12:00:00 GMTAntag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687 - Yahoo FinanceYahoo Finance · Tue, 28 Jul 2026 07:00:00 GMTYarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease - Business WireBusiness Wire · Mon, 27 Jul 2026 07:00:00 GMT